CD19 and acute lymphoblastic leukemia: Importantly, the same group demonstrated that CIK cells expanded from cord blood or PBMCs and then combined with Blinatumomab (CD3xCD19), significantly increased their killing capacity against an aggressive Ph+ CD19+ acute lymphoblastic leukemia PDX model in NOD-SCID mice, without signs of toxicity or GvHD (130).